PMID- 30370732
OWN - NLM
STAT- MEDLINE
DCOM- 20190612
LR  - 20190613
IS  - 1120-9763 (Print)
IS  - 1120-9763 (Linking)
VI  - 42
IP  - 5-6
DP  - 2018 Sep-Dec
TI  - [Pharmaceutical prescription of proton pump inhibitors and ranitidine in the 
      general population living in the area of the Healthcare Authority and University 
      of Udine (Friuli Venezia Giulia, Northeastern Italy)].
PG  - 308-315
LID - 10.19191/EP18.5-6.P308.099 [doi]
AB  - OBJECTIVES: to describe the use of proton pump inhibitors (PPI) and ranitidine in 
      the general population living in the area of the Healthcare Authority and 
      University of Udine (Friuli Venezia Giulia, Northeastern Italy) and to evaluate 
      whether there are any cases of co-prescription of medications in those classes. 
      DESIGN: analysis of health-related administrative databases (list of potential 
      healthcare beneficiaries, prescriptions of medications, exemption from medical 
      charges because of chronic conditions, list of general practitioners). SETTING 
      AND PARTICIPANTS: population of the Italian area of the Healthcare Authority and 
      University of Udine (approximately 250,000 inhabitants) >/=1 year of age as of 
      January 1st, 2016. MAIN OUTCOME MEASURES: prevalence of PPI or H2RA use (>1 
      prescription in 2016), overall and stratified by drug, age class and sex; 
      duration of the theoretical period covered by prescriptions; prevalence of 
      co-prescriptions; association of co-prescriptions and clinical and demographic 
      characteristics of patients (odds ratio and 95% confidence intervals). RESULTS: 
      in 2016, 162 persons per 1,000 used those medications; in particular, 158/1,000 
      used PPIs. Prevalence of use increased with age, as did the median treatment 
      duration with PPIs. Co-prescription of two medications of the same class were 
      observed in 0.43% of antacid users. The likelihood of receiving co-prescriptions 
      was higher among non-elderly subjects, long-term PPI users, and those with 
      chronical diseases, such asthma. CONCLUSION: in the considered Italian area, PPIs 
      and ranitidine were frequently used, although less than in the rest of Italy. We 
      observed occasionally non-recommended practices, such as the co-prescription of 
      different medications of the same class or with the same indications.
FAU - Valent, Francesca
AU  - Valent F
AD  - SOC istituto di igiene ed epidemiologia clinica, Azienda sanitaria universitaria 
      integrata di Udine; francesca.valent@asuiud.sanita.fvg.it.
FAU - Deroma, Laura
AU  - Deroma L
AD  - Direzione medica di presidio, Azienda sanitaria universitaria integrata di Udine.
FAU - Lattuada, Luca
AU  - Lattuada L
AD  - Direzione medica di presidio, Azienda sanitaria universitaria integrata di Udine.
FAU - Calligaris, Laura
AU  - Calligaris L
AD  - Distretto di Udine, Azienda sanitaria universitaria integrata di Udine.
FAU - Canciani, Luigi
AU  - Canciani L
AD  - Distretto di Udine, Azienda sanitaria universitaria integrata di Udine.
LA  - ita
PT  - Journal Article
TT  - La prescrizione farmaceutica territoriale di inibitori di pompa protonica e 
      ranitidina nella popolazione residente nell'area della Azienda sanitaria 
      universitaria integrata di Udine.
PL  - Italy
TA  - Epidemiol Prev
JT  - Epidemiologia e prevenzione
JID - 8902507
RN  - 0 (Proton Pump Inhibitors)
RN  - 884KT10YB7 (Ranitidine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Child, Preschool
MH  - Databases, Factual
MH  - Drug Prescriptions/*statistics & numerical data
MH  - Female
MH  - Health Information Systems
MH  - Humans
MH  - Infant
MH  - Italy
MH  - Male
MH  - Middle Aged
MH  - Proton Pump Inhibitors/*administration & dosage
MH  - Ranitidine/*administration & dosage
EDAT- 2018/10/30 06:00
MHDA- 2019/06/14 06:00
CRDT- 2018/10/30 06:00
PHST- 2018/10/30 06:00 [entrez]
PHST- 2018/10/30 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
AID - 10.19191/EP18.5-6.P308.099 [doi]
PST - ppublish
SO  - Epidemiol Prev. 2018 Sep-Dec;42(5-6):308-315. doi: 10.19191/EP18.5-6.P308.099.